Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study

Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
doi: https://doi.org/10.1101/2022.09.13.22279908

Data Availability

Upon request, and subject to review, Pfizer will provide the summary data that support the findings of this study.

Back to top
Posted September 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study
Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
medRxiv 2022.09.13.22279908; doi: https://doi.org/10.1101/2022.09.13.22279908
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area